Cidara Therapeutics, Inc. (CDTX)
Jan 7, 2026 - CDTX was delisted (reason: acquired by MRK)
221.38
+0.06 (0.03%)
Inactive · Last trade price on Jan 6, 2026

Cidara Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
CurrentQ3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021
Period Ending
Jan '26 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21 Jun '21 Mar '21
6,9742,8091,13226329476558472851021145545345782111100128
Market Cap Growth
2270.27%3608.39%1974.59%213.32%309.03%-11.06%-46.51%-26.59%31.21%90.53%201.52%98.89%-33.05%-59.78%-66.18%-55.25%-7.27%-11.23%-35.50%27.70%
Enterprise Value
6,5562,391623.5397.51108-47.69-105.5259.5641.0440.8656.167.3623.3-6.7611.4724.6727.2680.957.0192.22
Last Close Price
221.3895.7648.7121.5426.8810.7511.9418.4015.8818.8422.6025.4015.1312.569.7716.6525.4044.8040.4053.20
PS Ratio
---870.81230.7818.794.124.653.091.681.241.370.850.731.221.061.652.412.4110.75
PB Ratio
15.386.652.261.861.800.660.42-4.72-8.7610.606.624.26-3.804.93-4.2511.603.80-95.996.3367.89
EV/Sales Ratio
---322.8784.70-11.83-7.963.301.760.810.680.810.36-0.110.420.450.551.761.387.72
EV/EBITDA Ratio
-----0.370.90------0.20------
EV/EBIT Ratio
-----0.370.90------0.20------
EV/FCF Ratio
-----0.300.84------0.30------
Debt / Equity Ratio
0.000.000.000.020.020.030.03-0.26-0.590.540.290.04-0.080.18-0.290.740.23-5.480.343.51
Debt / EBITDA Ratio
-----------0.36-0.11----0.49-
Debt / FCF Ratio
----------1.67--0.06----1.55-
Asset Turnover
-000000.000.010.050.140.090.380.170.690.120.130.110.120.480.03
Quick Ratio
4.404.4015.863.483.862.914.210.550.741.451.782.070.931.760.941.411.911.211.521.07
Current Ratio
4.624.6216.453.874.253.544.250.720.901.621.982.231.091.931.161.622.111.411.801.28
Return on Equity (ROE)
-30.94%-30.94%-8.14%-37.90%-67.53%-25.12%-128.75%-180.57%72.24%-44.70%-165.44%18.95%-381.14%378.76%-335.18%-533.83%-104.08%-127.37%37.49%-65.75%
Return on Assets (ROA)
-26.03%-26.03%-7.74%-20.67%-38.45%-15.41%-79.54%-12.71%-15.21%-6.80%-12.64%4.06%-22.41%25.28%-25.40%-33.35%-24.71%-31.40%15.71%-26.35%
Return on Invested Capital (ROIC)
5118.57%5118.57%151.33%127.19%331.27%269.57%709.18%1581.85%84.59%113.11%-747.20%30.08%238.68%-771.41%-2403.85%1240.98%-474.94%-682.92%223.41%-780.22%
Return on Capital Employed (ROCE)
-32.78%-32.78%-8.62%-38.81%-65.73%-23.85%-112.74%-51.20%-305.35%-14.49%-30.24%8.03%-56.91%57.93%-69.15%-97.56%-53.10%-75.92%30.05%-53.04%
Buyback Yield / Dilution
-229.65%-311.67%-240.67%-212.44%-114.97%-44.65%-1.30%10.31%-25.88%-1.91%-30.33%-48.51%-11.51%-78.85%-16.54%-45.08%-46.03%-14.64%-44.31%-16.87%
Total Shareholder Return
-229.65%-311.67%-240.67%-212.44%-114.97%-44.65%-1.30%10.31%-25.88%-1.91%-30.33%-48.51%-11.51%-78.85%-16.54%-45.08%-46.03%-14.64%-44.31%-16.87%
SEC Filings: 10-K · 10-Q